NASDAQ: GLYCGlycomimetics Inc Stock
$1.71-0.15 (-8.06%)
Updated Apr 25, 2024
GLYC Price
$1.71
Fair Value Price
$0.65
Market Cap
$110.21M
52 Week Low
$1.11
52 Week High
$3.53
P/E
-2.95x
P/B
2.87x
P/S
14,949.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.00k
Earnings
-$36.90M
Gross Margin
100%
Operating Margin
-368,994.2%
Profit Margin
-368,994.2%
Debt to Equity
0.18
Operating Cash Flow
-$35M
Beta
1.23
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GLYC Overview
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GLYC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLYC ($1.71) is overvalued by 164.31% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLYC ($1.71) is not significantly undervalued (164.31%) relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLYC due diligence checks available for Premium users.
Be the first to know about important GLYC news, forecast changes, insider trades & much more!
GLYC News
Valuation
GLYC fair value
Fair Value of GLYC stock based on Discounted Cash Flow (DCF)
Price
$1.71
Fair Value
$0.65
Overvalued by
164.31%
GLYC ($1.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLYC ($1.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLYC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLYC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.95x
Industry
15.41x
Market
40.97x
GLYC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.87x
Industry
5.8x
GLYC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLYC's financial health
Profit margin
Revenue
$10.0k
Net Income
-$9.1M
Profit Margin
-90,786.4%
GLYC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GLYC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$45.3M
Liabilities
$6.9M
Debt to equity
0.18
GLYC's short-term assets ($43.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLYC's short-term assets ($43.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLYC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GLYC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
-$801.0
Financing
$999.0
GLYC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLYC vs Biotech Stocks
Glycomimetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.